| Literature DB >> 33806549 |
Krista Minéia Wartchow1,2, Benjamin Schmid3, Philipp Tripal3, Andreas Stadlbauer1, Michael Buchfelder1, Carlos-Alberto Gonçalves2, Andrea Kleindienst1.
Abstract
(1) Background: Despite progress in surgery and radio-chemotherapy of glioblastoma (GB), the prognosis remains very poor. GB cells exhibit a preference for hypoxia to maintain their tumor-forming capacity. Enhancing oxidative phosphorylation-known as the anti-Warburg effect-with cyclic AMP activators has been demonstrated to drive GB cells from proliferation to differentiation thereby reducing tumor growth in a cell culture approach. Here we re-evaluate this treatment in a more clinically relevant model. (2)Entities:
Keywords: 2-photon-microscopy; Warburg effect; glioblastoma; oxidative phosphorylation; treatment
Year: 2021 PMID: 33806549 PMCID: PMC8000435 DOI: 10.3390/cells10030556
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Experimental design. (A) Timeline. U87GFP+ cells (10,000 cells/0.1 µL medium) were implanted bilaterally into the CA3 region of the hippocampus 24 h after organotypic brain slice culture preparation. One intersection represents 24 h resp. 1 day. (B) Quantification of the tumor area.
Figure 2Visualization of the growth pattern of the glioblastoma cell line U87 co-cultured with organotypic brain slices. (A) As early as 48 h after transplantation, the tumor sphere demonstrated the first evidence of invasion as depicted by the green fluorescence of the human GB cell line U87GFP+; (B) the organotypic brain slices demonstrate a typical red fluorescence 2 h after propidium iodide staining; (C) the tumor growth on the surface of the organotypic brain slice is visualized on the merged figure; (D) One week after transplantation, the tumor demonstrated a considerable growth, and the GB typical invasion of the surrounding brain tissue; green fluorescence of U87GFP+; (E) red fluorescence 2 h after propidium iodide staining; (F) merged. Magnified by 20×. The scale bar represents 100 µm.
Assessment of metabolic effects in the culture medium of the glioblastoma cell line U87 co-cultured with organotypic brain slices over time. Data are expressed as mean ± SEM (n = 8 per group) for p < 0.5. * difference compared to No treatment. # difference compared to No tumor. $ difference compared to Forskolin. F is the ratio of the model to its error and is calculated by dividing the mean of squares for the model and the residual mean squares.
| Baseline | Treatment with dbcAMP or Forskolin | Statistics | |||
|---|---|---|---|---|---|
| Extracellular Medium | U87 Trans-Plantation | Treatment | Treatment | Treatment | Two-Way ANOVA |
| 48 h | Day 7 | Day 14 | |||
|
| F (3,137) = 2.257 | ||||
| No tumor | 435.89 ± 50.7 | 482.05 ± 49.23 | 550.86 ± 111.5 | 549.34 ± 43.16 | |
| No treatment | 506.75 ± 47.7 | 490.45 ± 132.9 | 530.66 ± 99.9 | 571.16 ± 79.85 | |
| 1 mM dbcAMP | 480.6 ± 100.5 | 463.49 ± 104.9 | 504.95 ± 86.81 | 557.08 ± 99.58 | |
| 50 μM Forskolin | 452.75 ± 56.2 | 458.04 ± 44.90 | 539.66 ± 68.95 | 502.60 ± 73.60 | |
|
| F (3,103) = 3.024 | ||||
| No tumor | 93.63 ± 56.23 | 85.37 ± 20.35 | 71.40 ± 19.99 | 53.48 ± 25.43 | |
| No treatment | 68.99 ± 32.78 | 53.75 ± 22.46 | 63.23 ± 20.99 | 120.23 ± 168.8 | |
| 1 mM dbcAMP | 68.46 ± 39.53 | 80.33 ± 20.31 | 65.50 ± 35.70 | 183.5 ± 137.5 *# | |
| 50 μM Forskolin | 71.12 ± 31.87 | 55.37 ± 20.75 | 39.85 ± 24.78 | 147.9 ± 155.0 *# | |
|
| F (3,144) = 1.758 | ||||
| No tumor | 6.14 ± 2.42 | 5.56 ± 2.48 | 7.15 ± 3.01 | 5.35 ± 1.46 | |
| No treatment | 6.45 ± 2.60 | 5.43 ± 2.09 | 5.95 ± 2.40 | 4.94 ± 3.90 | |
| 1 mM dbcAMP | 7.33 ± 2.50 | 5.39 ± 2.36 | 4.76 ± 1.93 | 5.71 ± 4.07 | |
| 50 μM Forskolin | 6.81 ± 3.07 | 4.74 ± 2.05 | 4.56 ± 1.55 | 3.01 ± 0.80 | |
|
| F (3,107) = 3.758 | ||||
| No tumor | 217.12 ± 88.7 | 183.5 ± 76.15 | 230.86 ± 29.51 | 44.90 ± 63.99 | |
| No treatment | 227.3 ± 65.7 | 153.0 ± 73.2 | 145.9 ± 96.1 | 147.6 ± 131.0 | |
| 1 mM dbcAMP | 179.6 ± 99.2 | 175.2 ± 107.5 | 226.2 ± 28.8 * | 236.2 ± 154.3 $# | |
| 50 μM Forskolin | 191.1 ± 101.1 | 90.3 ± 77.3 | 75.8 ± 110.9 * | 46.8 ± 67.4 | |
|
| F (3,113) = 0.4309 | ||||
| No tumor | 123.12 ± 35.7 | 138.13 ± 14.90 | 108.71 ± 51.40 | 148.56 ± 24.67 | |
| No treatment | 127.6 ± 27.5 | 103.6 ± 44.8 | 106.6 ± 21.9 | 111.7 ± 31.0 | |
| 1 mM dbcAMP | 114.9 ± 51.1 | 140.9 ± 36.4 | 132.8 ± 38.4 | 133.1 ± 91.2 | |
| 50 μM Forskolin | 121.1 ± 47.1 | 134.3 ± 68.6 | 108.2 ± 57.5 | 83.0 ± 43.7 | |
Figure 3Effect of differentiation therapy on the tumor area of the glioblastoma cell line U87 co-cultured with organotypic brain slices. U87GFP+ cells transplanted bilaterally onto the CA3 region of the hippocampus after organotypic brain slice preparation. (A) Fluorescent images at the start of culture, and 48 h, 7 days, and 14 days after treatment (a–d untreated glioblastoma; e–h treatment with the cyclic AMP analog dibutyryl cAMP; i–l treatment with the cAMP activator forskolin; magnified by 5×. The scale bar represents 500 µm. (B) Graphical depiction of the results of GB area measurements with ImageJ. Group comparisons were performed by two-way ANOVA followed by a Tukey post-hoc analysis. Data are expressed as mean ± SEM (n = 8 per group). * p < 0.5 untreated tumor vs. forskolin; # p < 0.5 untreated tumor vs. dbcAMP.
Figure 4Effect of differentiation therapy on the tumor volume of the glioblastoma cell line U87 co-cultured with organotypic brain slices as quantified by two-photon fluorescence microscopy. 3D images of U87GFP+ cells transplanted bilaterally onto the CA3 region of the hippocampus before, 7, and 14 days after treatment with the cyclic AMP analog dibutyryl cAMP and the cAMP activator forskolin. Scale bars represent 100 µm.